Trump’s Executive Order on U.S. Drug Pricing Draws Attention; Foresee Pharmaceuticals States CAMCEVI Currently Unaffected

Following U.S. President Donald Trump’s recent issuance of an executive order on drug pricing, concerns have emerged over the potential impact on pharmaceuticals sold in the U.S. by Taiwanese companies. In response, Foresee Pharmaceuticals issued a statement on the 16th, indicating that the global market deployment of its 505(b)(2) novel formulation drug, CAMCEVI, is currently unaffected by the recent executive order on drug pricing announced by President Trump.